Business Context and Reporting Period
This Form 8-K filing by Biorestorative Therapies, Inc. reports material events occurring on October 16, 2019. The company is an emerging growth company incorporated in Delaware. The filing details a material definitive agreement with a principal shareholder and unregistered sales of equity securities.
Key Financial Metrics and Capital Structure Changes
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. Instead, it reports specific capital structure transactions:
- Equity Issuance: Issued 3,333,333 shares of common stock to principal shareholder Dale Broadrick at $0.15 per share.
- Warrant Issuance: Granted a five-year warrant to Mr. Broadrick for 3,333,333 shares at an exercise price of $0.20 per share.
- Debt Financing: Issued a $100,000 convertible promissory note bearing 12% annual interest, maturing in April 2020. Conversion price is generally 60% of the fair value of common stock.
- Debt-for-Equity Swap: Issued 1,472,106 shares of common stock between October 10 and October 22, 2019, to settle $117,895 of outstanding indebtedness (including accrued interest).
Material Changes and Warrant Modifications
Significant modifications were made to existing warrant terms in consideration of the new agreement:
- Price Reduction: Exercise prices for outstanding warrants covering 1,055,556 shares were reduced from $0.70 to $0.15. Prices for warrants covering 1,055,555 shares were reduced from $0.85 to $0.15.
- Term Extension: Expiration dates for warrants covering 500,000 shares were extended from February 19, 2020, to February 19, 2024. Expiration dates for warrants covering 555,555 shares were extended from May 7, 2020, to May 7, 2024.
Outlook, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the inherent risks of the transactions described. The transactions were executed under Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933, relying on exemptions for private placements and exchanges with existing security holders. The company asserts that all investors were accredited and had access to financial information.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the fair value of the common stock used to calculate the conversion price for the new $100,000 convertible note.
- Review the full text of the Warrant (Exhibit 10.1) for additional terms not summarized in the 8-K.
- Assess the company's liquidity position given the issuance of new debt and the conversion of existing debt to equity.
- Check subsequent filings for any changes in the principal shareholder's ownership percentage following these transactions.